ZAY0 Stock Chart & Stats
€0.47
-€0.01(-2.46%)
At close: 4:00 PM EDT
€0.47
-€0.01(-2.46%)
Day’s Range― - ―
52-Week Range€0.32 - €0.90
Previous CloseN/A
Volume0.00
Average Volume (3M)266.00
Market Cap
€66.10M
Enterprise Value€60.34
Total Cash (Recent Filing)€16.60M
Total Debt (Recent Filing)€1.93M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding126,619,530
10 Day Avg. Volume0
30 Day Avg. Volume266
Financial Highlights & Ratios
PEG Ratio1.44
Price to Book (P/B)7.78
Price to Sales (P/S)459.28
P/FCF Ratio-13.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageModest leverage reduces refinancing and solvency pressure while preserving financial flexibility. This gives Zentek more capacity to fund product validation and commercialization without relying heavily on debt.
Equity CushionMeaningful equity provides a buffer against continued operating losses and supports investment in research, validation, and commercialization. It does not remove funding risk, but improves resilience compared with a highly leveraged balance sheet.
Broad Technology ApplicationsA platform spanning multiple end markets and commercialization routes can diversify future revenue opportunities. Success in one application, licensing channel, or strategic partnership could help reduce dependence on a single product.
Bears Say
Minimal And Declining RevenueVery limited and declining revenue indicates that commercialization remains at an early stage. Until sales scale materially, Zentek has little operating leverage and limited evidence that its technology portfolio can generate durable demand.
Persistent UnprofitabilityRepeated net losses and unstable margins indicate that the current business model has not yet reached economic viability. Continued losses can erode equity and may require additional financing before products achieve sustainable scale.
Ongoing Cash BurnNegative operating and free cash flow show that operations consume substantial cash rather than funding growth internally. This increases dependence on available liquidity or external capital to support R&D, validation, and commercialization.
Zentek News
ZAY0 FAQ
What was Zentek’s price range in the past 12 months?
Zentek lowest stock price was €0.32 and its highest was €0.90 in the past 12 months.
What is Zentek’s market cap?
Zentek’s market cap is €66.10M.
When is Zentek’s upcoming earnings report date?
Zentek’s upcoming earnings report date is Nov 16, 2026 which is in 89 days.
How were Zentek’s earnings last quarter?
Zentek released its earnings results on Aug 14, 2026. The company reported -€0.011 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Zentek overvalued?
According to Wall Street analysts Zentek’s price is currently Overvalued.
Does Zentek pay dividends?
Zentek does not currently pay dividends.
What is Zentek’s EPS estimate?
Zentek’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zentek have?
Zentek has 126,619,530 shares outstanding.
What happened to Zentek’s price movement after its last earnings report?
Zentek reported an EPS of -€0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Zentek?
Currently, no hedge funds are holding shares in DE:ZAY0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentek Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth €432.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
60.59%
Trailing 12-Months
Company Description
Zentek
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
Technical Analysis
Arch Biopartners
―
BioMark Diagnostics
―
Medexus Pharmaceuticals Inc
―
―
Sona Nanotech Inc
―